Our research aims to revolutionize drug development and patient care by delving into our genetic makeup. We are seeking access to the vast health, medical, and genetic data provided by the UK Biobank to identify novel drug targets and biomarkers, prioritize targets supported by human genetic evidence, discover potential adverse effects, and broaden drug indications.
By analyzing genetic variations and their impact on diseases, validated drug targets are expected to be more effective, with fewer side effects and higher chances of approval. We’ll also look at how diseases vary between different people, using both genetic and clinical information, to help match the right treatment to the right patient and improve clinical trial success rates.
Although this project will take approximately three years, we anticipate significant public health benefits for the population, including the accelerated development of safer and more effective drugs that will benefit a larger patient population.